Total saponin from Anemone flaccida Fr. Schmidt abrogates osteoclast differentiation and bone resorption via the inhibition of RANKL-induced NF-κB, JNK and p38 MAPKs activation

详细信息    查看全文

• 作者：Xiangying Kong ; Wenbin Wu ; Yue Yang ; Hongye Wan…
• 关键词：Anemone flaccida ; RANKL ; Osteoclasts ; Bone resorption ; MAPKs ; NF ; κB
• 刊名：Journal of Translational Medicine
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：13
• 期：1
• 全文大小：2,247 KB
• 参考文献：1. Matsuo, K (2009) Cross-talk among bone cells. Curr Opin Nephrol Hypertens 18: pp. 292-297 CrossRef
  2. Boyle, WJ, Simonet, WS, Lacey, DL (2003) Osteoclast differentiation and activation. Nature 423: pp. 337-342 CrossRef
  3. Cully, M (2013) Rheumatoid arthritis: Uncoupling bone and cartilage destruction. Nat Rev Rheumatol 9: pp. 446 CrossRef
  4. Ochi, S, Shinohara, M, Sato, K, Gober, HJ, Koga, T, Kodama, T (2007) Pathological role of osteoclast costimulation in arthritis-induced bone loss. Proc Natl Acad Sci U S A 104: pp. 11394-11399 CrossRef
  5. Broadhead, ML, Clark, JC, Dass, CR, Choong, PF, Myers, DE (2011) Therapeutic targeting of osteoclast function and pathways. Expert Opin Ther Targets 15: pp. 169-181 CrossRef
  6. Kukita, A, Kukita, T, Nagata, K, Teramachi, J, Li, YJ, Yoshida, H (2011) The transcription factor FBI-1/OCZF/LRF is expressed in osteoclasts and regulates RANKL-induced osteoclast formation in vitro and in vivo. Arthritis Rheum 63: pp. 2744-2754 CrossRef
  7. Lacey, DL, Timms, E, Tan, HL, Kelley, MJ, Dunstan, CR, Burgess, T (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: pp. 165-176 CrossRef
  8. Gohda, J, Akiyama, T, Koga, T, Takayanagi, H, Tanaka, S, Inoue, J (2005) RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis. EMBO J 24: pp. 790-799 CrossRef
  9. Asagiri, M, Takayanagi, H (2007) The molecular understanding of osteoclast differentiation. Bone 40: pp. 251-264 CrossRef
  10. Bai, S, Zha, J, Zhao, H, Ross, FP, Teitelbaum, SL (2008) Tumor necrosis factor receptor-associated factor 6 is an intranuclear transcriptional coactivator in osteoclasts. J Biol Chem 283: pp. 30861-30867 CrossRef
  11. Takayanagi, H (2007) Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7: pp. 292-304 CrossRef
  12. Banu, J, Varela, E, Fernandes, G (2012) Alternative therapies for the prevention and treatment of osteoporosis. Nutr Rev 70: pp. 22-40 CrossRef
  13. Han, LT, Li, J, Huang, F, Yu, SG, Fang, NB (2009) Triterpenoid saponins from Anemone flaccida induce apoptosis activity in HeLa cells. J Asian Nat Prod Res 11: pp. 122-127 CrossRef
  14. Bing, F, Zhang, G (2005) The national five kind of new medicine–rhizome of Anemone Flaccid Fengshi’an capsule. Hubei J Tradit Chin Med 27: pp. 48-49
  15. Han, LT, Fang, Y, Li, MM, Yang, HB, Huang, F (2013) The Antitumor Effects of Triterpenoid Saponins from the Anemone flaccida and the Underlying Mechanism. Evid Based Complement Alternat Med 2013: pp. 517931
  16. Nakashima, T, Takayanagi, H (2009) Osteoimmunology: crosstalk between the immune and bone systems. J Clin Immunol 29: pp. 555-567 CrossRef
  17. Jung, SM, Kim, KW, Yang, CW, Park, SH, Ju, JH (2014) Cytokine-mediated bone destruction in rheumatoid arthritis. J Immunol Res 2014: pp. 263-265 CrossRef
  18. Kong, X, Liu, C, Zhang, C, Zhao, J, Wang, J, Wan, H (2013) The suppressive effects of Saposhnikovia divaricata (Fangfeng) chromone extract on rheumatoid arthritis via inhibition of nuclear factor-kappaB and mitogen a
• 刊物主题：Biomedicine general; Medicine/Public Health, general;
• 出版者：BioMed Central
• ISSN：1479-5876

文摘

Osteoclasts, bone-specialized multinucleated cells, are responsible for bone destructive diseases such as rheumatoid arthritis and osteoporosis. Natural plant-derived products have received substantial attention given their potential therapeutic and preventive activities against bone destructive diseases. In the present study, we investigated the effects of total saponin (TS) from Anemone flaccida Fr. Schmidt, on receptor activator of nuclear factor-κB ligand (RANKL)-induced in vitro osteoclast differentiation. We observed that TS concentration-dependently inhibited RANKL-induced osteoclast formation from RAW 264.7 cell and bone marrow-derived macrophages (BMMs), as well as decreased extent of actin ring formation and lacunar resorption. The RANKL-stimulated expression of osteoclast-related transcription factors were also diminished by TS. Moreover, TS blocked the RANKL-triggered TRAF6 expression, phosphorylation of mitogen-activated protein kinases (MAPKs) and IκB-α, and inhibited NF-κB p65 DNA binding activity. Furthermore, TS almost abrogated the nuclear factor of activated T cells (NFATc1) and c-Fos expression. Taken together, our results demonstrated that TS suppresses RANKL-induced osteoclast differentiation and inflammatory bone loss via the down-regulation of TRAF6 level, suppression of JNK and p38 MAPKs and NF-κB activation, and subsequent decreased expression of c-Fos and NFATc1. Therefore, TS may be a potential agent and needs to be more evaluated in vivo or in clinical trials to become a therapeutic for lytic bone diseases.